Achieving Clinical NGS Laboratory Excellence through College of American Pathologists (CAP) Laboratory Accreditation Program in Vietnam and Beyond


We are delighted to announce an important milestone: Medical Genetics JSC, a subsidiary of Gene Solutions group, has become an accredited Next Generation Sequencing (NGS) laboratory in Vietnam by the prestigious College of American Pathologists (CAP). This accreditation signifies our compliance with the highest standards in laboratory testing, particularly in the category of high complexity testing as per CLIA or CAP guidelines in the United States.

CAP’s Laboratory Accreditation Program is designed to ensure the highest standards of laboratory quality and accuracy through its stringent standards and comprehensive audit processes (1). During this rigorous evaluation, laboratories undergo thorough inspections of their records, quality control procedures, staff qualifications, equipment, facilities, safety programs, and overall management. Pursuing CAP accreditation signifies a laboratory’s dedication to quality and proficiency, going beyond the listed requirements of CLIA.

By meeting CAP’s stringent criteria and achieving CAP accreditation, we join an exclusive group of over 8,000 laboratories worldwide known for their excellence in laboratory medicine and pathology.(1)

Benefits for Our Clinical Customers

Enhanced Accuracy and Reliability

With CAP accreditation, our clinical customers can be confident that the test results they receive from are accurate, reliable, and consistent. This level of trust is crucial for making informed medical decisions, leading to better patient outcomes.

Commitment to Quality

CAP accreditation signifies our unwavering commitment to quality in every aspect of our laboratory operations. This commitment translates to fewer errors, more accurate diagnoses, and ultimately, higher standards of patient care.

Advanced Testing Capabilities

Achieving CAP accreditation often requires laboratories to adopt the latest technologies and methodologies. Our clinical customers benefit from state-of-the-art testing capabilities that provide more precise and comprehensive diagnostic information.

Improved Turnaround Times

The rigorous quality control measures associated with CAP accreditation help streamline laboratory processes. This means faster turnaround times for test results, allowing healthcare providers to make timely decisions and improve patient care.

Continuous Improvement

CAP accreditation is not a one-time event but an ongoing process. Our journey reflects on our ongoing commitment to advancing healthcare through continual innovation and excellence. We are enthusiastic about the opportunities this accreditation opens for us to further elevate healthcare standards and make a positive impact on healthcare outcomes in our region.
We extend gratitude to our dedicated team at Gene Solutions and our valued partners for their continuous support in achieving this significant milestone. Together, we steadfast in our mission to revolutionize healthcare through cutting-edge genetic solutions.

“We are incredibly proud to achieve CAP lab accreditation, marking a significant moment for Medical Genetics JSC within the Gene Solutions Group. This recognition underscores our commitment to ensuring the highest standards of accuracy and reliability in Next Generation Sequencing (NGS) based genetic testing. It reflects the hard work and dedication of our team, and we are excited about the positive impact this achievement will have on advancing healthcare standards in Vietnam and Southeast Asia.” – Dr. Thanh, Laboratory Head, Medical Genetics JSC

MGI CAP certificate 2024
MGI CAP certificate 2024

(1) https://uatcap.objects.frb.io/documents/2018-guide-to-accreditation.pdf

LATEST News

New Study Validates Gene Solutions’ Upgraded ctDNA Workflow Behind K-TRACK and K-4CARE

New Study Validates Gene Solutions’ Upgraded ctDNA Workflow Behind K-TRACK and K-4CARE

Peer-reviewed findings published in The Journal of Liquid Biopsy, an official journal of the International Society of Liquid Biopsy (ISLB), demonstrate broader ctDNA analysis, improved recurrence prediction, and greater flexibility with or without tumor tissue. SINGAPORE, 14 October 2026 – Gene Solutions announced the publication of a new peer-reviewed study validating the upgraded ctDNA workflow behind K-TRACK, K-4CARE, and K-TRACK Blood Only. Published in The Journal of Liquid Biopsy, an official journal of the International Society of Liquid Biopsy (ISLB), the study evaluated how Gene Solutions’ new hybrid-capture sequencing workflow and VarSURE bioinformatics pipeline improve upon its previous amplicon-based ctDNA method.

Read More

Biomarker and ctDNA Testing: A Personalized Approach to Cancer Care

Cancer diagnosis often brings many questions: Which treatment is most suitable for me? Is my treatment working? Has cancer changed? Could it come back? Every person’s cancer is different. Even when two people have the same type of cancer, their tumors may have different biological features. These differences can influence how the cancer behaves and how it responds to treatment. Biomarker and circulating tumor DNA, or ctDNA, testing may help doctors better understand these differences. Together, these tests may support more personalized treatment decisions and provide additional information as the cancer changes over time. Why can the same cancer respond

Read More
Gene Solutions NIPT preterm birth prenatal health

Gene Solutions Study Finds Preterm-Birth Signals in Routine triSure NIPT Data

A Gene Solutions study published in American Journal of Obstetrics & Gynecology (AJOG) Global Reports finds cell-free DNA fragmentomic patterns associated with spontaneous preterm birth, pointing to a potential path toward earlier pregnancy-risk assessment. SINGAPORE, Sept. 25, 2026 /PRNewswire/ — Gene Solutions, a global biotechnology company providing precision cell-free DNA solutions through multi-omics and artificial intelligence to improve pregnancy care, cancer detection and precision medicine, today announced the publication of a study showing the potential to assess the risk of spontaneous preterm birth from cell-free DNA fragmentomic signals already present in routine first-trimester non-invasive prenatal testing (NIPT) data. Published in AJOG Global Reports, the

Read More